 |
Astex Receives Milestone from Wellcome Trust for Pioneering HCV Research
Feb 1, 2011
|
11.0 KB |
|
| |
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, announced that it has received a milestone payment of £1 million from the Wellcome Trust to support the Company’s pioneering work in the area of infectious disease caused by Hepatitis C Virus (HCV). The payment is the second...
|
|
Astex Announces Milestone in Oncology Collaboration
Jan 11, 2011
|
11.4 KB |
|
| |
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, announced that it has received a milestone payment from its collaboration with Novartis. The milestone payment was triggered by the initiation of a first-in-human clinical trial of investigational anti-cancer drug LEE011. LEE011 derive...
|
|
SuperGen Announces Enrollment of First Patient in First in Human Trial of SGI-110 in MDS and AML Patients
Jan 5, 2011
|
8.0 KB |
|
| |
DUBLIN, Calif., Jan 05, 2011 (BUSINESS WIRE) --SuperGen, Inc. (NASDAQ:SUPG) today announced that it has enrolled the
first patient in its first in human study of SGI-110, a
second-generation hypomethylating agent, in patients with intermediate-2
or high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia...
|
|
SuperGen Announces Presentation of SGI-110 Preclinical Data at American Society of Hematology
Dec 3, 2010
|
7.1 KB |
|
| |
DUBLIN, Calif., Dec 03, 2010 (BUSINESS WIRE) --SuperGen, Inc. (NASDAQ:SUPG) today announced that a summary of
preclinical efficacy, safety, and pharmacokinetics data of SGI-110 will
be presented at the American Society of Hematology in Orlando on
Saturday, December 4, 2010 at 5:30 pm ET. The title of the poster
...
|
|
Encouraging Data on Astex’s Anti-Cancer Drug AT9283 to be Presented at ASH
Dec 1, 2010
|
23.1 KB |
|
| |
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, today announced presentations of new data on its combinatorial oncogenic kinase inhibitor AT9283. The presentations will be made during the 52nd American Society of Hematology Meeting, 4-7th December in Orlando.
AT9283 in ...
|
|
SuperGen Pipeline Presentations at EORTC-NCI-AACR
Nov 15, 2010
|
6.1 KB |
|
| |
DUBLIN, Calif., Nov 15, 2010 (BUSINESS WIRE) --SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the
discovery and development of novel cancer therapies, today announced the
acceptance of three abstracts detailing recent work with SuperGen
compounds. Poster presentations by SuperGen and collaborat...
|
|
Encouraging Data from Phase I Studies of Astex’s Anti-Cancer Drugs AT7519, AT9283 and AT13387 to be Presented at EORTC-NCI-AACR Annual Meeting
Nov 11, 2010
|
67.8 KB |
|
| |
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, today announced presentations of new clinical data on three of its novel anti-cancer agents and on an advanced drug discovery programme aimed at identifying non-peptidic selective inhibitors of the IAP (inducers of apoptosis) class of ...
|
|
SuperGen Discontinues Clinical Development of SGI-1776
Nov 10, 2010
|
6.4 KB |
|
| |
DUBLIN, Calif., Nov 10, 2010 (BUSINESS WIRE) --SuperGen, Inc. (NASDAQ:SUPG) today announced that it has discontinued
clinical development of its phase 1 PIM kinase drug candidate, SGI-1776,
while continuing development of the PIM inhibitor program.
The dose limiting toxicity of cardiac QTc prolongation was identi...
|
|
Astex and the NCIC Clinical Trials Group Announce Start of Phase II Clinical Study of AT9283 in Multiple Myeloma
Nov 4, 2010
|
13.1 KB |
|
| |
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the NCIC Clinical Trials Group in Canada, announced today the initiation of a Phase II clinical trial of Astex’s combinatorial oncogenic kinase inhibitor, AT9283, to treat patients with relapsed or refractory multiple myeloma, a...
|
|
Milestone transition in Astex Alzheimer’s Disease collaboration with AstraZeneca
Oct 25, 2010
|
11.1 KB |
|
| |
Astex Therapeutics, the UK based biotechnology company developing targeted therapies for oncology and virology, announced today that AstraZeneca has selected a candidate drug from its collaborative drug discovery programme aimed at identifying novel, small molecule inhibitors of beta-secretase - a key enzyme implicated in the progression of Alzheim...
|
|
SuperGen Reports 2010 Third Quarter Financial Results
Oct 25, 2010
|
21.3 KB |
|
| |
...
|
|
Astex and Multiple Myeloma Research Consortium (MMRC) Announce Start of Phase II Clinical Study of AT7519 in Multiple Myeloma
Aug 12, 2010
|
15.4 KB |
|
| |
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium (MMRC) announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase (CDK) inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an ...
|
|
SuperGen Reports 2010 Second Quarter Financial Results
Aug 2, 2010
|
27.1 KB |
|
| |
DUBLIN, Calif., Aug 02, 2010 (BUSINESS WIRE) --SuperGen, Inc. (NASDAQ:SUPG) today reported financial results for the
second quarter and six months ended June 30, 2010.
"The second quarter was profitable. Our Dacogen partners Eisai and
Johnson & Johnson have reaffirmed their respective intentions to file
...
|
|
Astex scientists describe novel HSP90 inhibitors in two key publications in Journal of Medicinal Chemistry
Jul 29, 2010
|
11.1 KB |
|
| |
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, announced today that two key papers detailing its fragment-based drug discovery approach to heat shock protein 90 (HSP90) inhibitors have been published back-to-back in the industry-leading Journal of Medicinal Chemistry*.
The ...
|
|
Dacogen® (Decitabine) for Injection Phase III AML Results Announced
Jun 30, 2010
|
9.6 KB |
|
| |
DUBLIN, Calif., Jun 30, 2010 (BUSINESS WIRE) --SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the
discovery and development of novel cancer therapies, announced that
Eisai Inc. today released information regarding a randomized Phase III
clinical trial of Dacogen®...
|
|
Encouraging Interim Data From A Phase I Study Of Astex’s HSP90 Inhibitor AT13387 To Be Presented At ASCO
Jun 2, 2010
|
15.9 KB |
|
| |
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, announced that interim data from an ongoing Phase I study of its novel HSP90 inhibitor, AT13387, is to be presented at the American Society of Clinical Oncology Annual Meeting, June 4-8, 2010, in Chicago, USA.
The Phase I study...
|
|
SuperGen to Present in New York on June 8 and 9
Jun 2, 2010
|
5.2 KB |
|
| |
DUBLIN, Calif., Jun 02, 2010 (BUSINESS WIRE) --SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the
discovery and development of novel cancer therapies, today announced
that James S.J. Manuso, Ph.D., President and Chief Executive Officer,
will present at the Jefferies Global Life Sciences Conference on ...
|
|
SuperGen Reports 2010 First Quarter Financial Results
Apr 26, 2010
|
20.7 KB |
|
| |
DUBLIN, Calif., Apr 26, 2010 (BUSINESS WIRE) --SuperGen, Inc. (NASDAQ: SUPG) today reported financial results for the
first quarter ended March 31, 2010.
"SuperGen made significant progress on all critical fronts during the
first quarter of 2010, including strengthening our financial position,
augmenting our tea...
|
|
Encouraging data from three Astex collaborative programmes to be presented at the 101st American Association for Cancer Research (AACR) Annual Meeting 2010
Apr 13, 2010
|
26.0 KB |
|
| |
Astex will chair the mini-symposium on “New Preclinical and Clinical Candidates” which will include the first disclosure of new anticancer agents from a number of research groups. Astex scientists will present new biological and pharmacological data on compounds from its FGFr inhibitor programme which was partnered with Janssen Phar...
|
|
SuperGen Reports 2009 Fourth Quarter and Year-End Financial Results
Mar 1, 2010
|
24.9 KB |
|
| |
DUBLIN, Calif., Mar 01, 2010 (BUSINESS WIRE) -- SuperGen Inc., (NASDAQ:SUPG), a pharmaceutical company dedicated to the
discovery and development of novel cancer therapies, today reported
financial results for the fourth quarter and year ended December 31,
2009.
The Company reported net income for the 2009 fourth quar...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter